NASDAQ:GEVA - Synageva Biopharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Synageva BioPharma Corp. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for the treatment of rare diseases. The Company has a pipeline of protein therapeutic programs for rare diseases. Its lead product is Kanuma (sebelipase alfa) being developed for the treatment of lysosomal acid lipase deficiency (LAL Deficiency). The Company's other product candidates under development include SBC-103, a first-mover enzyme replacement therapy program for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) and SBC-105, which is a first-mover enzyme therapy in preclinical development for rare disorders of calcification, including the indication generalized calcification in infants (GACI). The Company also has additional first-mover and potentially bio-superior protein therapeutic pipeline programs for other rare diseases at different stages of preclinical development.

Receive GEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for GEVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:GEVA
Previous Symbol
CUSIP87159A10
Phone+1-781-3579900

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Synageva Biopharma (NASDAQ:GEVA) Frequently Asked Questions

What is Synageva Biopharma's stock symbol?

Synageva Biopharma trades on the NASDAQ under the ticker symbol "GEVA."

How were Synageva Biopharma's earnings last quarter?

Synageva Biopharma Corp (NASDAQ:GEVA) released its earnings results on Thursday, February, 26th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.71) by $0.02. The biopharmaceutical company had revenue of $1.24 million for the quarter, compared to analysts' expectations of $1.25 million. View Synageva Biopharma's Earnings History.

Has Synageva Biopharma been receiving favorable news coverage?

Headlines about GEVA stock have trended very positive on Monday, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Synageva Biopharma earned a media sentiment score of 3.9 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term.

How do I buy shares of Synageva Biopharma?

Shares of GEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synageva Biopharma's official website?

The official website for Synageva Biopharma is http://www.synageva.com.

How can I contact Synageva Biopharma?

Synageva Biopharma's mailing address is 33 Hayden Ave, LEXINGTON, MA 02421-7972, United States. The biopharmaceutical company can be reached via phone at +1-781-3579900.


MarketBeat Community Rating for Synageva Biopharma (NASDAQ GEVA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  317
MarketBeat's community ratings are surveys of what our community members think about Synageva Biopharma and other stocks. Vote "Outperform" if you believe GEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2018 by MarketBeat.com Staff

Featured Article: Growth Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel